Therapy
Biotechnology
Medical

Dermira

$12.99
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.63 (-4.63%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Dermira and other stocks, options, ETFs, and crypto commission-free!

About

Dermira, Inc. Common Stock, also called Dermira, is a biopharmaceutical company, which engages in the provision of therapies for chronic skin conditions. Read More It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis and atopic dermatitis. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Menlo Park, CA.

Employees
333
Headquarters
Menlo Park, California
Founded
2010
Market Cap
549.84M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.04M
High Today
$13.78
Low Today
$12.85
Open Price
$13.40
Volume
962.58K
52 Week High
$14.91
52 Week Low
$6.00

Collections

Therapy
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
Health
2014 IPO

News

Seeking AlphaMar 22

Dermira closes $150M capital raise

Dermira (NASDAQ:DERM) has closed its public offering of ~11.3M shares of common stock at $13.25 per share, including the full exercise of ~1.5M shares by underwriters.

91
Markets InsiderMar 22

Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

MENLO PARK, Calif., March 22, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the closing of its previously announced underwritten public offering of 11,283,019 shares of its common stock, including 1,471,698 shares sold upon full exercise of the underwriters’ option to purchase additiona...

65
The Motley FoolMar 19

Can Dermira Stock Keep Soaring?

There are 6.6 million Americans with a form of eczema that their doctors can't control with standard treatment. Dermira (NASDAQ:DERM) recently reported results for a potential new treatment aimed at this underserved group, and investors liked what they saw enough to send the stock soaring 82% in a single day. A successful launch of lebrikizumab would lift the small-cap biotech's share price several times higher, but the mid-stage candidate also faces plenty of hazards along the way. Here's what you need to...

742

Earnings

-$1.74
-$1.33
-$0.92
-$0.51
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 2, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.